Author

Anaelys Maceo

OpenAlex ID: A5077219982

A first‐in‐class, first‐in‐human, phase I trial of CIGB ‐552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF‐κB in patients with advanced solid tumors

2021 · Maribel G. Vallespi, Braulio Mestre, et al. · International Journal of Cancer · 7

Works count: 1

Citation count: 7

H-index: 1

I10-index: